Abivax reports positive data from ABX464 study for HIV-related inflammation

French biotechnology firm Abivax has reported positive findings from the evaluation of the ability of its product candidate ABX464 to mitigate intestinal inflammation in HIV patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news